Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103

NCT04643886 is registered in ClinicalTrials.gov with Gemini Therapeutics, Inc. as lead sponsor.

NCT NCT04643886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04643886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
Lead sponsor
Gemini Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 30, 2020
Completion date
March 21, 2022
Enrollment
62 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration, geographic atrophy, macular degeneration, retinal degeneration, retinal disease